Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?

European Journal of Cancer

Volumn 32, Issue 3, 1996, Pages 450-454

  Van Holten Verzantvoort, A T M ^a   Hermans, J ^a   Beex, L V A M ^b   Blijham, G ^c,e   Cleton, F J ^a   Van Eck Smit, B C F ^a   Sleeboom, H P ^d   Papapoulos, S E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEYENBURG HOSPITAL   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Bisphosphonates; Bone metastases; Breast cancer; Pamidronate

Indexed keywords

PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; QUALITY OF LIFE; RISK FACTORS; SURVIVAL RATE;

EID: 0029968633     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00564-1     Document Type: Article

References (14)

1. Elte JWF, Bijvoet OLM, Cleton FJ, van Oosterom AT, Sleeboom HP. Osteolytic bone metastasis in breast carcinoma: pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol 1986, 22, 493-500.
2. Lee Y-TM. Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 1985, 4, 153-72.
3. Koenders PG, Beex LV, Langens R, et al. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat 1991, 18, 27-32.
4. Rubens RD, Bartelink H, Engelsman E, et al. Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. Eur J Cancer Clin Oncol 1989, 25, 667-678.
5. Elomaa I, Blomqvist C, Gröhn P, et al. Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet 1983, i, 146-149.
6. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 59-65.
7. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al. Palliative pamidronate (APD) treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11, 491-98.
8. Van Holten-Verzantvoort ATM, Bijvoet OLM, Cleton FJ, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987, ii, 983-985.
9. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, et al. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 1991, 27, 544-9.
10. Winer BJ. Statistical Principles in Experimental Design. New York, McGraw Hill, 1971.
11. Kamby C, Ejlertsen B, Andersen J, et al. The pattern of metastasis in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. Acta Oncol 1988, 27, 715-719.
12. Krempien B, Manegold Chr. Prophylactic treatment of skeletal metastases, tumour-induced osteolysis, and hypercalcaemia in rats with the bisphosphonate C12MBP. Cancer 1993, 72, 91-98.
13. Conte PF, Latreille J, Mauriae L, Koliren L, Ford JM. Aredia infusions in breast cancer: a randomized phase III trial to assess delay in progression of bone metastases. Bone Miner 1994, 25, S78.
14. Papapoulos SE, van Holten-Verzantvoort ATM. Modulation of tumour-induced bone resorption by bisphosphonates. J Steroid Biochem Mol Biol 1992, 43, 131-136.